Principal Investigator: Subodh Devabhaktuni, M.D., Assistant Professor, Division of Cardiology, Department of Internal Medicine, College of Medicine.
Summary: A phase 3 multi-center efficacy and safety study of Etripamil Nasal Spray to treat spontaneous episodes of Paroxysmal Supraventricular Tachycardia (PSVT), an arrhythmia.
Significance: While not lethal, PSVT episodes can cause panic that sends patients to the emergency department. If approved by the FDA, Etripamil Nasal Spray could be used in the home to stabilize patients’ heart rhythms.
TRI Services: Budget development and negotiation, Medicare coverage analysis, and regulatory management
Sponsor: Milestone Pharmaceuticals Inc.